Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31280686 | 0.86 | ALDH1A1 (0.42) | ALDH1A1HSD17B10CYP1A2HPGDHIF1A | |
| SCHEMBL5702406 | 0.76 | CYP1A2 (0.42) | ALDH1A1HSD17B10CYP1A2HPGDHIF1A | |
| SCHEMBL20957573 | 0.75 | PTPN22 (0.35) | ALDH1A1HSD17B10HPGDTSHRCASP1 | |
| SCHEMBL29413773 | 0.74 | GRK6 (0.42) | ALDH1A1HSD17B10CYP1A2HPGDTSHR | |
| SCHEMBL29988480 | 0.74 | GRK6 (0.42) | ALDH1A1HSD17B10CYP1A2HPGDTSHR | |
| SCHEMBL8113 | 0.74 | GRK6 (0.42) | ALDH1A1HSD17B10CYP1A2HPGDTSHR | |
| SCHEMBL25508 | 0.74 | ALDH1A1 (0.50) | ALDH1A1HSD17B10CYP1A2HPGDHIF1A | |
| SCHEMBL30879493 | 0.74 | ALDH1A1 (0.50) | ALDH1A1HSD17B10CYP1A2HPGDHIF1A | |
| SCHEMBL10615759 | 0.72 | MPO (0.38) | ALDH1A1HSD17B10HIF1ACASP1TDP1 | |
| Hydrochloric Acid SCHEMBL11423023 | 0.72 | GRK6 (0.41) | ALDH1A1HSD17B10CYP1A2HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4461895-A | FOR COMBATTING COLDS AND ALLERGIES | WARNER-LAMBERT COMPANY (US) | 1984-07-24 | — | — | US | claimed |
| US-20230141988-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES | ACLIPSE ONE INC. | 2023-05-11 | — | — | US | disclosed |
| EP-2640395-A2 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | Omeros Corporation (US) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012064667-A2 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | OMEROS CORPORATION (US) | 2012-05-18 | — | — | WO | disclosed |
| EP-2427193-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | Omeros Corporation (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129036-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | OMEROS CORPORATION (US) | 2010-11-11 | — | — | WO | disclosed |
| US-4461895-A | FOR COMBATTING COLDS AND ALLERGIES | WARNER-LAMBERT COMPANY (US) | 1984-07-24 | — | — | US | disclosed |
| US-4461895-A | FOR COMBATTING COLDS AND ALLERGIES | WARNER-LAMBERT COMPANY (US) | 1984-07-24 | — | — | US | disclosed |
| US-4461895-A | FOR COMBATTING COLDS AND ALLERGIES | WARNER-LAMBERT COMPANY (US) | 1984-07-24 | — | — | US | disclosed |
| EP-0064685-A1 | Dibenzo(de,g)quinolines, processes for their preparation and pharmaceutical preparations containing them | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1982-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141988-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES | PARK7, SNCA, ATXN10 | ALDH1A1 573/4885HSD17B10 606/4885CYP1A2 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.